Gene Therapy – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034

 Gene Therapy Market Outlook

Thelansis’s “Gene Therapy Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Gene Therapy treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Gene Therapy Overview

Gene therapy is a cutting-edge medical approach that involves manipulating a person’s genes to treat or even cure diseases. This revolutionary technique encompasses various mechanisms to achieve its objectives:

1. Replacing Faulty Genes: One approach is substituting disease-causing genes with healthy counterparts, effectively restoring normal gene function within the individual’s cells.
2. Inactivating Dysfunctional Genes: Some gene therapies focus on deactivating genes malfunctioning or causing diseases, thereby mitigating their harmful effects.
3. Introducing Modified Genes: Another method involves introducing new or modified genes into the body to combat specific diseases or medical conditions.

Primarily confined to research laboratories, gene therapy is still experimental. However, it rapidly evolves into a viable therapeutic option and combines gene therapy with other treatments like immune modulation, chemotherapy, and radiotherapy. Gene therapy can be broadly classified into two categories: germinal and somatic. Germinal gene therapy involves introducing genes into somatic cells and an individual’s germline. It not only cures the genetic disease but can also pass the altered trait to some of the individual’s gametes. On the other hand, somatic gene therapy targets non-reproductive or somatic tissues to correct genetic diseases. Dysfunctional cells are removed and replaced with cloned wild-type genes. These corrected genes then provide the necessary function to alleviate disease symptoms. Typically, not all affected cells need modification, only enough to alleviate symptoms. Gene therapy products are being researched for their potential to treat diseases such as cancer, genetic disorders, and infectious diseases. Several types of gene therapy products are being explored:

1. Plasmid DNA: Circular DNA molecules engineered to carry therapeutic genes into human cells.
2. Viral Vectors: Modified viruses with their infectious capabilities removed, used as vehicles to deliver therapeutic genes into human cells.
3. Bacterial Vectors: Non-harmful bacteria serving as carriers to transport therapeutic genes into human tissues.
4. Human Gene Editing Technology: Gene editing aims to disrupt harmful genes or repair mutated ones.
5. Patient-Derived Cellular Gene Therapy Products: Cells are extracted from the patient, genetically modified (often using viral vectors), and reintroduced into the patient’s body.

Gene therapy holds immense promise for the future of medicine, offering effective treatment and potential eradication of a wide range of diseases.

 

Geography coverage:

G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)

Insights driven by robust research, including:

• In-depth interviews with leading KOLs and payers
• Physician surveys
• RWE analysis for claims and EHR datasets
• Secondary research (e.g., peer-reviewed journal articles, third-party research databases)

Deliverables format and updates*:

• Detailed Report (PDF)
• Market Forecast Model (MS Excel-based automated dashboard)
• Epidemiology (MS Excel; interactive tool)
• Executive Insights (PowerPoint presentation)
• Others: regular updates, customizations, consultant support

*As per Thelansis’s policy, we ensure that we include all the recent updates before releasing the report content and market model.

Salient features of Market Forecast model:

• 10-year market forecast (2024–2034)
• Bottom-up patient-based market forecasts validated through the top-down sales methodology
• Covers clinically and commercially-relevant patient populations/ line of therapies
• Annualized drug-level sales and patient share projections
• Utilizes our proprietary Epilansis and Analog tool (e.g., drug uptake and erosion) datasets and conjoint analysis approach
• Detailed methodology/sources & assumptions
• Graphical and tabular outputs
• Users can customize the model based on requirements

Key business questions answered:

• How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)?
• How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments?
• What is the 10-year market outlook for sales and patient share?
• Which events will have the greatest impact on the market’s trajectory?
• What insights do interviewed experts provide on current and emerging treatments?
• Which pipeline products show the most promise, and what is their potential for launch and future positioning?
• What are the key unmet needs and KOL expectations for target profiles?
• What key regulatory and payer requirements must be met to secure drug approval and favorable market access?
• and more…

Read more: Gene Therapy – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034